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INTRODUCTION
Since the pioneering experiments of Peter Medawar in the 1950s,
immunosuppressive drugs have been used to inhibit the immune
rejection of organ transplants in man (Medawar, 1958). Although
early approaches were based upon cortisone and azathioprine, the
discovery of the calcineurin inhibitor cyclosporin A in the 1970s
was a major breakthrough that enabled transplantation to become
an established therapy (Green and Allison, 1978). In the subsequent
four decades, organ transplantation has emerged as an effective
treatment for end-stage organ failure, as well as for diseases such
as type 1 diabetes mellitus (Watson and Dark, 2012). In the USA
there were more than 28,000 organ transplants in 2008
(http://www.srtr.org/) with this number increasing every year. The
macrolide calcineurin inhibitor tacrolimus (FK506) was licensed
for use in transplantation by the FDA in 1994, and it has now
replaced cyclosporin A as the first-line calcineurin inhibitor in solid
organ transplantation because of improved outcomes (Moore and
Lord, 1994; Watson and Dark, 2012). FK506 binds to FKBP12 in
T cells and this complex mediates calcineurin inhibition, and also
blocks T cell signal transduction via NFAT and interleukin-2 (IL-
2) transcription (Tamura et al., 1994). Thus, the major mechanism
of action of FK506 is to inhibit T-cell-dependent transplant
rejection. However, recent studies have also demonstrated that
calcineurin negatively regulates the Toll-like receptor signalling
pathway (Kang et al., 2007) that is required for innate C-type lectin
signalling (Greenblatt et al., 2010). These observations suggest a
more widespread effect of calcineurin inhibitors on both innate as
well as adaptive immune responses.
Organ transplant recipients are at an increased risk of a number
of different bacterial, viral and opportunistic fungal infections
(Fishman, 2011). There is a clear association between calcineurin
inhibitors and the opportunistic infections cytomegalovirus,
hepatitis C, BK virus and invasive fungal pathogens (Kotton and
Fishman, 2005; Fishman, 2007; Pappas et al., 2010). Comprehensive
surveillance data from the US TRANSNET registry shows that solid
organ transplant patients have an overall risk of 3.1% per annum
for proven or probable IFIs, and that this risk continues for at least
3 years post-transplantation (Pappas et al., 2010). The overall
mortality from IFIs in these patients is ~40%. The primary
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SUMMARY
Invasive fungal infections (IFIs) are a major cause of death in organ transplant patients. The murine hydrocortisone-mediated immunosuppression
model of pulmonary aspergillosis is commonly used to characterise IFIs in these patients. However, this model does not take into account the effects
of calcineurin inhibitors on transplant immunity to IFIs or the fungal calcineurin pathway, which is required for both virulence and antifungal drug
resistance. To address these two issues, a new and clinically relevant transplant immunosuppression model of tacrolimus (FK506) and hydrocortisone-
associated pulmonary aspergillosis was developed. We first characterised IFIs in 406 patients with a lung transplant. This showed that all of the
patients with pulmonary aspergillosis were immunosuppressed with calcineurin inhibitors and steroids. Murine pharmacokinetic studies demonstrated
that an ideal dose of 1 mg/kg/day of FK506 intraperitoneally produced blood trough levels in the human therapeutic range (5-12 ng/ml). There was
increased mortality from pulmonary aspergillosis in a transplant-relevant immunosuppression model using both FK506 and hydrocortisone as
compared with immunosuppression using hydrocortisone only. Lung histopathology showed neutrophil invasion and tracheobronchitis that was
associated with reduced lung tumour necrosis factor-α (TNFα), JE (homologue of human MCP-1) and KC (homologue of human IL-8) at 24 hours,
but increased lung TNFα, JE and KC at 48  hours when fungal burden was high. Furthermore, FK506 directly impaired fungal killing in alveolar
macrophages in vitro, with FK506-mediated inhibition of the radial growth of Aspergillus fumigatus in vitro occurring at the low concentration of 
5 ng/ml. Taken together, these findings show that the immunosuppressive activity of FK506 outweighs its antifungal activity in vivo. These observations
demonstrate that FK506 impairs innate immune responses and leads to an incremental increase in susceptibility to IFIs when it is combined with
steroids. This new and clinically relevant mouse model of invasive aspergillosis is a valuable addition to the further study of both fungal immunity
and antifungal therapy in organ transplantation.
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pathogens responsible are Candida spp., A. fumigatus and
Cryptococcus neoformans. Furthermore, and in contrast to stem
cell transplantation, neutropenia is not a significant driver for IFI
in organ transplantation, suggesting that the immunological
determinants of susceptibility to infection are different to those that
have already been defined (Baddley et al., 2010). Animal models
that accurately represent the immunosuppressive drug regimens
in current clinical use in solid organ transplantation patients are
therefore needed to understand the pathogenesis of these life-
threatening infections.
Cyclosporin A was first isolated from the soil fungus
Tolypocladium inflatum, by Novartis in 1972 during an extensive
screen for immunosuppressive compounds (Rüegger et al., 1976).
Cyclosporin A complexes with cyclophilin and directly inhibits
calcineurin. Similarly, FK506 was first isolated from the
actinomycete Streptomyces tsukabaensis (Ochiai et al., 1987). In
fungi, both drugs are known to inhibit calcinueurin signalling,
which is required for conidial germination, hyphal growth and
tissue invasion (Fox and Heitman, 2002). Previous studies in a
murine model of haematogenous aspergillosis indicated that
cyclosporin A reduces the length of survival but that FK506 has
no net effect (High and Washburn, 1997). However, aspergillosis
is not acquired by the haematogenous route, but by the pulmonary
route. Although earlier studies showed that neither
immunosuppressive drug had an effect on invasive candidiasis,
recent studies have shown that cyclosporin A impairs innate
immunity (Greenblatt et al., 2010). In these studies, the effect of
steroids combined with calcineurin inhibitors in transplantation
was not investigated.
Taken together, these observations suggest a complex relationship
between the effects of calcineurin inhibitors on fungal virulence,
host defence and antifungal therapy. Therefore, clinically relevant
models of transplant invasive fungal infections are now required
to better understand these crucial interactions. The key
requirements for such a model are: (i) to account for the compound
effects of different transplant immunosuppressive drugs on disease
outcome; (ii) to enable characterisation of immunosuppressive drug
pharmacokinetics so that they are relevant to human
transplantation; (iii) an appropriate route of infection and organ
specificity of the disease; (iv) the genetic tractability of the murine
model, (v) a disease pathology in mice that accurately reflects the
disease in humans; and (vi) cross-correlation with existing models
of aspergillosis in mice. This study has addressed all these issues
in a new murine model of transplant pulmonary aspergillosis.
RESULTS
Lung transplant patients immunosuppressed with steroids and
FK506 are at high risk of pulmonary aspergillosis
We first characterised the immunosuppressive drug regimens and
the incidence of invasive aspergillosis in a cohort of lung transplant
recipients. Prospective surveillance of a cohort of 406 lung
transplant patients was undertaken over a 6-month period to
determine their incidence of proven or probable pulmonary
aspergillosis using the revised EORTC criteria (De Pauw et al.,
2008). Proven cases were defined as biopsy-proven invasive
aspergillosis. Probable cases were defined as patients with a positive
BAL (broncho-alveolar lavage) culture for Aspergillus sp. and
radiological evidence of invasive aspergillosis (macronodules, halo
sign or air crescent sign) or tracheobronchitis (tree-in-bud). We
did not include possible cases. There were 39 patients with proven
or probable IFIs, of whom 19 had pulmonary aspergillosis; this was
equivalent to a 12-month incidence of 9% for pulmonary
aspergillosis. Eleven patients had Aspergillus tracheobronchitis, and
eight patients had invasive aspergillus disease. All of the patients
with aspergillosis had been maintained on prednisolone-mediated
immunosuppression and calcineurin inhibitors. Sixteen patients
were receiving FK506 and three patients were receiving
cyclosporine. A further 12 patients were also receiving
mycophenolate mofetil, and three patients azathioprine.
FK506 inhibits A. fumigatus growth in vitro at transplant-relevant
concentrations
To determine whether the immunosuppressive drug FK506 has
significant antifungal activity at concentrations that are
physiologically relevant to clinical transplantation, we first defined
the minimum inhibitory concentration for FK506 against A.
dmm.biologists.org2
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TRANSLATIONAL IMPACT
Clinical issue
Invasive fungal infections (IFIs) are a major cause of death among organ
transplant recipients, who have to be immunosuppressed to inhibit T-cell-
mediated organ rejection. Recipients of solid organ transplants have an overall
risk of about 3% per annum of IFIs, and their mortality from IFIs is about 40%,
despite the availability of antifungal drugs with good in vitro activity. Studies
in humans suggest that organ transplant recipients who succumb to IFIs have
an impaired peripheral blood interferon-γ response and that such patients
benefit from adjunctive recombinant human interferon-γ therapy.
Immunosuppression for organ transplantation currently consists of a
combination of a steroid and a calcineurin inhibitor such as tacrolimus (FK506).
Importantly, in addition to immunosuppressive activity, calcineurin inhibitors
have antifungal activity and interact with other antifungals in vitro.
Results
Most studies of fungal infections in organ transplantation are undertaken in a
hydrocortisone-mediated immunosuppression murine model of invasive
pulmonary aspergillosis, a model that fails to take into account the effects of
calcineurin inhibitors. In this study, the authors develop a FK506-
hydrocortisone combination murine model of invasive aspergillosis. They
determine the FK506 dose that achieves a blood trough in male BALB/c mice
equivalent to human therapeutic levels in transplantation and show that the
combination of FK506 and hydrocortisone increases mortality in mice with
invasive pulmonary aspergillosis compared with hydrocortisone alone. In mice
immunosuppressed with FK506 and hydrocortisone with invasive pulmonary
aspergillosis, examination of the lung histopathology, analysis of the
expression of pulmonary inflammatory cytokines and chemokines in the mice,
and Aspergillus fumigatus infection assays in murine alveolar macrophages
indicate that the immunosuppressive activity of FK506 outweighs its
antifungal activity in vivo and in vitro.
Implications and future directions
These findings introduce a new and clinically relevant murine model for
invasive pulmonary aspergillosis. Despite the in vitro antifungal activity of
calcineurin inhibitors, these findings show that FK506-mediated
immunosuppression in mice with invasive pulmonary aspergillosis leads to
heightened inflammation and necrosis in the lung and tracheobronchitis, and
increases mortality from pulmonary aspergillosis, probably because of a
calcineurin-dependent defect of fungal killing in alveolar macrophages. This
new murine model has the potential to provide insights into the immunity to
IFIs in organ transplant recipients, and can also be used for preclinical studies
of antifungal drug efficacy.
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fumigatus CEA10 using the EUCAST microbroth dilution method
(Subcommittee on Antifungal Susceptibility Testing of the ESCMID
European Committee for Antimicrobial Susceptibility Testing,
2008). The minimum inhibitory concentration (MIC) for FK506
was 16 μg/ml; however, morphological changes (microcolonies and
increased frequency of hyphal branching) could be seen at doses
down to 0.5 μg/ml. For this reason, we then further analysed the
effects of FK506 with the more sensitive radial growth assay on
both Sabaraud and RPMI agar (Fig. 1). Using this approach, we
found that the radial growth of A. fumigatus CEA10 was
significantly inhibited by FK506 at concentrations that were
equivalent to the trough serum levels in patients on maintenance
drug therapy to prevent organ rejection (5-12 ng/ml; Fig. 1). There
was no significant effect on growth rates for hydrocortisone at
concentrations from 0.5 to 1000 μg/ml (data not shown).
Human-equivalent FK506-mediated immunosuppression does not
enable establishment of murine pulmonary aspergillosis with a
standard inoculum of A. fumigatus
In order to produce a clinically relevant model of transplant
aspergillosis, we then undertook dose-ranging studies for FK506
to define the ideal dosing regimen required to produce a human-
equivalent 12-hour therapeutic trough level. FK506 was given as
daily and incremental intraperitoneal (i.p.) doses. All trough
concentrations were assayed on whole blood taken 12 hours after
the third dose (84  hours). These initial dose-ranging studies
demonstrated that, for FK506, the ideal human-relevant dosage was
1 mg/kg i.p. daily (mean trough concentration 6.9 ng/ml, s.e.m. 0.58;
Fig. 2). Incremental dose-finding studies defined the LD50 (dose at
which 50% of animals die) for tacrolimus as 20 mg/kg daily i.p. (data
not shown).
We then compared the survival of BALB/c mice infected with an
intranasal inoculum of 5×106 A. fumigatus CEA10 conidia after
immunosuppression from day 3 prior to infection (day −3) with either
hydrocortisone (125 or 250 mg/kg subcutaneously, s.c., every 3 days)
or FK506 (1 mg/kg i.p. daily). These studies showed that although
80% mortality was seen by day 9 using 250 mg hydrocortisone/kg
s.c. every 3 days, and 60% mortality using 125 mg hydrocortisone/kg
i.p. every 3 days, there was no mortality for FK506 (used alone) at
1, 5, 10 or 15 mg/kg up to 10 days post-infection (data not shown).
RT-PCR for fungal burden and histopathological analysis by periodic
acid-Schiff (PAS) stain showed no evidence of infection in any of
these animals at day 10 post-infection.
FK506 causes incremental mortality from pulmonary aspergillosis
when combined with steroids
We then compared the effect of immunosuppression by a
combination of  FK506 and hydrocortisone on the outcome for
pulmonary aspergillosis with the effect of hydrocortisone alone. In
two independent experiments, groups of eight BALB/c mice were
immunosuppressed with 125 mg/kg hydrocortisone every 3 days
from day −3 with or without the addition of 1 mg/kg FK506 daily
i.p. These studies showed incremental mortality from invasive
pulmonary aspergillosis in the FK506-hydrocortisone
immunosuppression model (100% by day 5) compared with
immunosuppression using hydrocortisone only (75% mortality by
day 5, P<0.0041; Fig. 3A). We observed that all mice initially had
dyspnoea, including those that subsequently survived in the steroid
group, which was consistent with recovery from significant
aspergillus infection. FK506 did not cause increased weight loss in
sham PBS-infected animals immunosuppressed with
hydrocortisone (supplementary material Fig. S1A). Weight loss data
for A. fumigatus-infected mice indicated that weight loss was
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Fig. 1. Determination of the effect of FK506 on A. fumigatus growth at a
human-therapeutic trough concentration by radial growth assay.
(A,B)Radial growth of A. fumigatus strains CEA10, AF293 and ATCC46645 was
measured at defined time points after inoculation of 1×103 conidia onto
Sabaroud (A) or RPMI (B) media with or without 5 ng/ml FK506 and incubation
at 37°C. Data are shown for triplicates measurements for each of the three
strains tested. The detection limit indicates the width of the Petri dish.
Fig. 2. Determination of ideal i.p. dosage of FK506 to produce human-
therapeutic trough concentrations in blood. Whole blood levels of FK506
were measured by LC-MS at 12 hours after the third injection of FK506 i.p.
daily. All FK506 dosages were given according to body weight. Mice received
1, 2.5, 5 or 7.5 mg FK506/kg/day. Data are shown as mean ± s.e.m. of triplicate
measurements. Dotted lines indicate the upper and lower limits for the trough
therapeutic ranges for the drugs in transplant recipients.
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greatest in the combined immunosuppression group
(supplementary material Fig. S1B). Analysis of the fungal burden
at 6, 24 and 48 hours post-infection showed an increase in the fungal
burden in the animals treated with FK506 and hydrocortisone
(P<0.021; Fig. 3B). Furthermore, analysis of fungal killing in murine
alveolar macrophages indicated a clear killing defect that was
dependent upon FK506 (Fig. 3C).
In order to determine whether the increased mortality in the
FK506-hydrocortisone model was independent of fungal strain or
mouse strain, we repeated these experiments in groups of eight
mice using either a C57BL/6 background or with the A. fumigatus
isolates AF293 or ATCC46645. These experiments confirmed the
incremental mortality for the FK506-hydrocortisone model with
both the sequenced strain AF293 and the clinical isolate
ATCC46645 (Fig. 4). Survival studies in the C57BL/6 background
mouse showed that they were also susceptible to the effects of
FK506, with an incremental increase in mortality in the mice treated
with FK506 and hydrocortisone (100% at day 5) as compared with
the hydrocortisone-only group (50% at day 5, P<0.0016) (Fig. 4C).
In invasive aspergillosis, FK506-mediated immunosuppression
results in increased pulmonary inflammation and an increase in
JE, KC and TNFα
We then undertook a histopathological analysis of the lungs from
mice with pulmonary aspergillosis. Groups of three mice were
immunosuppressed with hydrocortisone, FK506 plus
hydrocortisone, or FK506 alone and the lungs harvested at 48 hours
post-infection. Sections were stained by PAS and scored.
Inflammation was quantified by threshold particle analysis using
ImageJ software. There was incremental parenchymal inflammation
in the mice immunosuppressed with both FK506 (1 mg/kg) and
hydrocortisone (125 mg/kg) compared with the hydrocortisone-
only (125 mg/kg) group (Fig. 5A). Hematoxylin and eosin (H&E)
staining and Grocott sections from the lung tissue showed acute
inflammation that surrounded and involved the airways. Some of
the airways were occluded by an infiltrate (Fig. 5B). In others, the
bronchial epithelium was disrupted and destroyed by the
inflammatory response (Fig. 5B). Also noted were multiple areas
of patchy consolidation with destruction of the lung parenchyma;
there was often near-complete obliteration of the lung architecture
by the acute inflammatory response. The cellular infiltrate was
composed of neutrophils and histiocytes. Grocott silver staining
showed a large number of septate fungal hyphae branching at acute
angles and with the presence of bulbous heads.
In order to determine the effects of FK506 immunosuppression
on pulmonary cytokine and chemokine production, we then
performed Luminex multianalyte profiling (MAP) cytokine analysis
on whole lung homogenates and BAL samples in mice
immunosuppressed with FK506 and hydrocortisone at 24 and
48  hours post-infection. These studies showed that
immunocompetent mice (i.e. untreated) infected with A. fumigatus
had significantly higher levels of JE (homologue of human MCP-
1), KC (homologue of human IL-8) and tumour necrosis factor-α
(TNFα) in their lungs at 24 hours compared with mice treated with
either hydrocortisone or FK506 plus hydrocortisone (Fig. 6A). In
immunocompetent mice, JE, KC and TNFα fell to near normal
levels by 48  hours. This contrasted with hydrocortisone-treated
animals, in which JE, KC and TNFα increased significantly. The
highest levels of JE, KC and TNFα were seen at 48  hours post-
infection in the lungs of the mice treated with FK506 and
hydrocortisone (Fig.  6A). There were no significant increases in
interferon-γ, IL-2, IL-4, IL-6 or IL-13. We further characterised
neutrophil and macrophage numbers in the alveolar space by
dmm.biologists.org4
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Fig. 3. Survival from pulmonary aspergillosis and fungal burden in
BALB/c mice immunosuppressed with FK506 and hydrocortisone.
(A)Survival from pulmonary aspergillosis. Two groups of eight BALB/c mice
were immunosuppressed with either hydrocortisone (125 mg/kg s.c. every 3
days) or with hydrocortisone (125 mg/kg s.c. every 3 days) in combination with
FK506 (1 mg/kg i.p. daily) from day −3. They were then intranasally inoculated
with 5×106 A. fumigatus CEA10 conidia. Data are shown as mean from the two
independent experiments. Survival differences were determined by Kaplan-
Meier analysis. (B)Time course of pulmonary fungal burden. Groups of three
mice were either untreated or immunosuppressed with FK506, hydrocortisone
or both and sacrificed at 6, 24 and 48 hours post-infection and lungs
harvested. Total DNA was isolated and A. fumigatus fungal burden estimated
by semi-quantitative RT-PCR in comparison with murine β-actin. Statistical
significance was determined by linear regression analysis. Data are shown as
mean ± s.e.m. (C)Killing of A. fumigatus by murine alveolar macrophages. The
alveolar macrophage cell line MH-S was pre-treated either with 10 ng/ml
FK506 or with carrier. The ability to kill A. fumigatus CEA10 was assayed at
6 hours post-infection at an MOI of 1 by RT-PCR for fungal RNA after
normalisation to control. p.i., post-infection; HC, hydrocortisone; Mac, alveolar
macrophage; AF, A. fumigatus.
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fluorescence activated cell sorting (FACS) analysis of broncho-
alveolar lavage samples at 24 hours post-infection. These studies
did not demonstrate any significant difference in inflammatory cell
numbers in infected animals (Fig. 6B,C).
DISCUSSION
IFIs have emerged as a major cause of morbidity and mortality in
organ transplant patients (Pappas et al., 2010) who are
immunosuppressed with steroids and calcineurin inhibitors.
However, this immunosuppressive drug regimen is not represented
in current standard animal models of invasive fungal infections,
which are typically based upon hydrocortisone alone (Sheppard et
al., 2006). We have therefore developed a new model of murine
immunosuppression using both FK506 and hydrocortisone. This
model will enable detailed and clinically more representative
mechanistic studies of disease pathogenesis and of antifungal drug
evaluation. Importantly, this model has evolved from our existing
standard hydrocortisone model of invasive aspergillosis and should
therefore ensure that the outcomes can be compared with those
relating to virulence, immunity and therapy from previous mouse
studies (Tang et al., 1993).
Despite the in vitro antifungal activity of FK506 at transplant-
therapeutic concentrations, due to the presence of the calcineurin
pathway in fungi (Heitman et al., 1994), we found that mice
immunosuppressed with hydrocortisone plus FK506 had an
incremental mortality from pulmonary aspergillosis compared
with the established hydrocortisone murine model. Paradoxically,
this was associated with a significant increase in lung fungal burden,
with the results reproducible in BALB/c mice, C57BL/6 mice, the
genome-sequenced strains AF293 and CEA10, as well as the
clinical isolate ATCC46645. There was histopathological evidence
of increased parenchymal and trancheobronchial inflammation as
assessed through blind scoring by a consultant histopathologist.
Disease Models & Mechanisms 5
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Fig. 4. Incremental mortality in the FK506-hydrocortisone
immunosuppression model is independent of murine or fungal strain.
Groups of eight (A,B) male BALB/c and (C) male C57BL/6 mice were
immunosuppressed with hydrocortisone (125 mg/kg s.c. every 3 days) alone
or in combination with FK506 (1 mg/kg i.p. daily) from day −3, and then
intranasally inoculated with 5×106 A. fumigatus AF293 (A), ATCC46645 (B) or
CEA10 (C) conidia. Survival differences were determined by Kaplan-Meier
analysis. p.i., post-infection; HC, hydrocortisone; FK, FK506.
Fig. 5. Immunosuppression with FK506 and hydrocortisone leads to
increased inflammation in invasive pulmonary aspergillosis. Groups of
three mice were either untreated or immunosuppressed with FK506,
hydrocortisone or both and culled at 48 hours after infection. Lungs were fixed
and three PAS stained sections from each mouse scored with ImageJ software
by threshold analysis for the amount of inflammation. (A)Percentage of lung
area inflamed (histopathology). (B)Representative Grocott-stained (right) and
H&E-stained (left) lung sections for the combined FK506-hydrocortisone
model, demonstrating airways occluded by inflammatory cells and fungal
germlings, together with inflammation in and around the airway and damage
to the bronchial epithelium. IC, immunocompetent; HC, hydrocortisone.
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It was not possible to establish an FK506 monotherapy
immunosuppression model of pulmonary aspergillosis without the
use of a large fungal inoculum (5×107 conidia). Under these
conditions, a hyperacute disease developed that was characterised
by acute respiratory failure, dense peribronchial hyphal infiltrates
and death within 24 hours. This syndrome was not consistent with
the pattern of clinical disease in transplant patients, which is
typically much less acute (Pappas et al., 2010). By contrast, we were
able to demonstrate incremental susceptibility to infection in the
more clinically representative FK506 plus steroid combination
immunosuppression murine model. Dosing with 1 mg/kg FK506
i.p. daily enabled establishment of 12-hour trough levels of FK506
that were equivalent to those seen in human transplant patients
(5-12 ng/ml). This resulted in an increase in mortality from 80%
in the baseline hydrocortisone model to 100% in the FK506-
hydrocortisone model. These observations suggest that the
combination of steroids with calcineurin inhibitors is a key driver
for susceptibility to fungal infection in organ transplant recipients.
This is consistent with our observations in man where the ‘at risk’
population is typically immunosuppressed with a combination of
steroids and calcineurin inhibitors.
The finding of incremental mortality with therapeutic levels of
FK506 strongly suggests that calcineurin inhibitors contribute to
increased susceptibility to IFIs in transplantation. Notably, our in
vitro studies demonstrate that therapeutic concentrations of FK506
(e.g. 5-12 ng/ml) significantly impair radial growth of A. fumigatus
in the EUCAST standard RPMI-based medium. However, and
paradoxically, our in vivo studies demonstrated that similar dosages
lead to higher fungal burden in the lung and increased mortality.
This suggests that the immunosuppressive effects of FK506
outweigh its antifungal potential in this murine model, a finding
that was reproducible across three different fungal strains (CEA10,
AF293 and ATCC46645) and two mouse strains (BALB/c and
C57BL/6). These findings were also consistent with those
demonstrated in murine alveolar macrophages that exhibited
impaired fungal killing in the presence of FK506. Taken together,
the reults suggest that the calcineurin pathway contributes to innate
immune responses to A. fumigatus and, as such, are consistent with
prior observations in Candida albicans (Greenblatt et al., 2010).
Further studies are required to define the molecular mechanisms
underlying this phenotype. We also noted that a significant number
of lung transplant patients with pulmonary aspergillosis also receive
mycophenolate mofetil; however, our studies to date indicate that
its addition to the immunosuppressive drug regimen does not
increase susceptibility to IFIs in this murine model (unpublished
observations).
The calcineurin pathway is highly conserved in eukaryotic
organisms (Aramburu et al., 2004). In Saccharomyces cerevisiae,
the primary targets of cyclosporin and FK506 have been shown to
be cyclophillin and FKBP12, respectively. Both drugs have also been
shown to have potent antifungal activity in C. neoformans, and A.
fumigatus (Foor et al., 1992; Odom et al., 1997; Steinbach et al.,
2007a). Previous microbroth dilution studies defined a geometric
MIC of 1.25 μg/ml for FK506 against a range A. fumigatus strains;
however, these studies employed the NCLS method (National
Committee for Clinical Laboratory Standards, 2002) rather than
the EUCAST method, and the strains tested differed (Steinbach et
al., 2004). In comparison, although we found that the MIC for the
highly-virulent genome-sequenced strain CEA10 was 16 μg/ml, we
went on to assess the radial growth of three A. fumigatus strains
on EUCAST agar. These studies indicated that the impaired radial
growth still occurred at the much lower patient blood trough
therapeutic concentration of 5 ng/ml of FK506 for all of the strains
tested (CEA10, Af293 and ATCC46645).
These observations raise the possibility that FK506 has significant
effects on fungal growth in vivo in transplant patients. Interestingly,
in C. albicans, calcineurin inhibitors do not inhibit growth unless
they are used in combination with azole antifungals such as
fluconazole (Marchetti et al., 2000). Further studies have shown
synergism of calcineurin inhibitors with the echinocandin class of
antifungals that inhibit cell wall 1,3-β-glucan synthesis (Steinbach
et al., 2007b). This suggests that significant interactions could 
exist between the calcineurin inhibitor drugs used as
immunosuppressants in transplantation and the antifungal drugs
used to treat IFIs. Thus, the development of a new murine
transplant immunosuppression model of pulmonary aspergillosis
that is based on a combination of steroid and FK506 will enable
the further and detailed study of calcineurin inhibitor interactions
with multiple drugs in a clinically relevant model. Its direct
comparability to our current hydrocortisone immunosuppression
dmm.biologists.org6
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Fig. 6. Immunosuppression with FK506 and hydrocortisone
leads to increased levels of TNFα, JE and KC in the lung in
invasive aspergillosis. (A)Groups of three mice were either
untreated or immunosuppressed with hydrocortisone or FK506 plus
hydrocortisone and culled at 24 and 48 hours after infection with
5×106 A. fumigatus CEA10 conidia. Saline controls were uninfected.
Lungs were homogenised and supernatant levels of TNFα, JE and
KC measured by Luminex MAP analysis. Statistical significance was
determined by one-way ANOVA and Tukey’s test. (B,C)Groups of
three mice were either untreated or immunosuppressed with
FK506, hydrocortisone or both and culled at 24 hours after infection
with 5×106 A. fumigatus CEA10 conidia. (B)FACS analysis for
neutrophil influx into the bronchoalveolar space. There were no
significant differences between infected groups. (C)FACS analysis
for macrophages in the bronchoalveolar space. There were no
significant differences between infected groups. Sham, uninfected
group; HC, hydrocortisone; IC, immunocompetent; BAL,
bronchoalveolar lavage. Data are shown as mean and s.e.m.
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model or the cyclophosphamide-induced neutropenia model is
important because the same mouse strain, fungal strain, inoculum
and steroid immunosuppression regimen were used.
Histopathological analysis of the lungs from FK506-hydrocortisone
immunosuppressed mice with pulmonary aspergillosis demonstrated
incremental inflammation defined by increased polymorphonuclear
and histiocytic cell infiltrates and tissue necrosis in the lung compared
with the baseline hydrocortisone immunosuppression model.
Notably, there was an increase in tracheobronchial inflammation
associated with numerous visible hyphae within the airway.
Interestingly, Aspergillus tracheobronchitis is a disease syndrome that
is particularly associated with lung transplant patients, suggesting
that the combination of FK506 and hydrocortisone might, in some
way, contribute to this disease (Kramer et al., 1991). It is further
conceivable that the antifungal properties of calcineurin inhibitors
alter the pathology of the disease and lead to a mucosally restricted
phenotype.
Our characterisation of pulmonary Aspergillus infections in 406
lung transplant patients over a 6-month period found an incidence
of 39 cases of proven or probable IFI, of which 19 were due to
pulmonary aspergillosis. Of these, 58% had tracheobronchitis as
their clinical diagnosis, with all except one patient receiving steroids
and a calcineurin inhibitor at the time of diagnosis. This was a
clinical demonstration of the association of the steroid and
calcineurin drug regimen with an increased susceptibility to IFIs.
Aspergillus tracheobronchitis is common in other groups of organ
transplant patients and this also suggests a relationship with
calcinerin inhibitor use. In order to further determine the
mechanism that leads to increased inflammation and a cellular
infiltrate in the lung in our new mouse model, we undertook
Luminex® Fluorokine® MAP cytokine analysis of whole mouse lung
homogenates. Immunocompetent mice showed an early (24 hours)
pro-inflammatory response to pulmonary aspergillosis with high
levels of lung TNFα, JE and KC compared with hydrocortisone-
only immunosuppressed mice. However, by 48 hours, there was a
dramatic reduction in lung cytokine production in
immunocompetent mice that was associated with rapid fungal
eradication, whereas mice immunosuppressed with hydrocortisone
or FK506 plus hydrocortisone continued to increase their lung
TNFα, JE and KC. These changes were greatest in the combination
FK506-hydrocortisone murine model where the fungal burden was
also highest. This suggests an initial failure to generate an adequate
and appropriate innate cytokine response in the transplant model
at 24  hours, followed by a late sustained cytokine response at
48 hours that is associated with the presence of the fungal pathogen
in the lung. Therefore, the inflammatory cytokine TNFα, the
macrophage chemokine JE and the neutrophil chemokine KC might
drive the continuing cell-mediated inflammatory pathology in this
model. These observations lead us to hypothesise that calcineurin
inhibition might directly impair innate fungal killing. Our studies
in murine alveolar macrophages further support these findings,
where exposure to FK506 significantly impaired killing of A.
fumigatus in vitro. Taken together, these in vitro and in vivo
observations strongly suggest that FK506 impairs fungal killing in
alveolar macrophages, leading to increased fungal burden in the
lung. This increased fungal burden appears to drive a sustained
hyperinflammatory response in the lung, leading to tissue
destruction and increased mortality. Further studies are required
to confirm these preliminary observations and to further define
the relationship between tracheobronchitis, chemokine expression
and calcineurin inhibition.
In summary, we have developed a new mouse model of
pulmonary aspergillosis that is based upon immunosuppression
with FK506 and hydrocortisone and is relevant to organ
transplantation as it is practised today. Because IFIs have emerged
as a major cause of morbidity and mortality in this rapidly
expanding group of patients, the hydrocortisone-only mouse model
for studies of host immunity, immunotherapy and antifungal
therapy is no longer suitable (Pappas et al., 2010). It should now
be possible to obtain a better understanding of the complex drug
interactions that occur and to enable the development of rational
strategies to improve the outcome for those patients with life-
threatening IFIs.
MATERIALS AND METHODS
Estimation of prevalence of pulmonary aspergillosis in lung
transplant patients
We prospectively identified lung transplant patients at the Royal
Brompton and Harefield NHS Trust (London, UK) who started
antifungal drug therapy over a 6-month period. This study was
approved by the ethics committee of the Royal Brompton and
Harefield NHS Trust Biomedical Research Unit. Case notes were
reviewed and patients categorised into proven, probable and
possible invasive aspergillosis according to the revised EORTC
criteria (De Pauw et al., 2008). Probable aspergillus
tracheobronchitis was defined as typical bronchoscopic
appearances (tracheobronchitis with or without ulceration) or
radiographic appearances (tree-in-bud) in the presence of positive
bronchoscopic culture for A. fumigatus in patients with otherwise
unexplained deterioration in lung function and no other identified
cause. Immunosuppressive regimens at the initiation of antifungal
drug therapy were identified from electronic pharmacy records.
A. fumigatus strains and growth conditions
A. fumigatus CEA10 was the primary isolate used. A. fumigatus
293 and ATCC46645 were used for confirmatory studies. For in
vivo studies, strains were cultured on solid Aspergillus complete
medium (ACM) for 3-5 days (Barratt et al., 1965) prior to harvest
in 0.1% Tween and then filtered through MIRACLOTH
(Calbiochem, UK). Conidial suspensions were washed twice in
sterile normal saline (Baxter Healthcare, UK), enumerated by
haemocytometry and re-suspended at the concentrations indicated.
For in vitro studies, all radial growth and minimum inhibitory
concentration assays were performed according to European
Committee on Antimicrobial Susceptibility Testing (EUCAST)
procedures (Subcommittee on Antifungal Susceptibility Testing of
the ESCMID European Committee for Antimicrobial Susceptibility
Testing, 2008). Stock FK506 (Cambridge Bioscience, UK) was re-
suspended in 100% ethanol at 5  mg/ml, and diluted in RPMI
medium (Sigma, UK). The drug was added to EUCAST medium
at the desired concentration as indicated.
Murine infections
All mouse experiments were approved by the United Kingdom Home
Office and performed in accordance with project license PPL
70/7324. Groups of five BALB/c or C57BL/6 male mice (18-22 g;
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Harlan Ortech, UK) were housed in individually vented cages with
free access to autoclaved food and water. Mice received
hydrocortisone (Hydrocortistab, Sovereign Medical) by s.c. injection
and FK506 (Prograf, Astellas) by i.p. injection at the concentrations
and time-points shown. All mice received 1  mg/l tetracycline
hydrochloride (Sigma) and 64 mg/l ciprofloxacin (Sigma) in drinking
water as prophylaxis against bacterial infections. Mice were
anaesthetised by isoflourane inhalation and intranasally inoculated
with the indicated number of A. fumigatus conidia in 40 μl of normal
saline. For mortality studies, mice were culled at 20% weight loss as
a UK Home Office established end-point and organs harvested.
For histopathological studies, lungs were fixed in 10% buffered
formalin for 24 hours and embedded in paraffin. Sections (4 μm) were
stained with PAS, H&E or Grocott stains. Analysis of lung
histopathological inflammation was performed using ImageJ software
(rsb.info.nih.gov/ij/). Quantitative analysis of total lung area 
was performed by threshold particle analysis in ImageJ
(http://rsbweb.nih.gov/ij/). Further thresholding procedures were
performed within selective areas of inflammation that were visually
identified and a subsequent percentage affected proportion calculated.
FK506 concentration in blood
Blood was taken by terminal cardiac puncture and stored in
Microcontainer K2E tubes (Becton Dickinson). Whole blood FK506
concentrations were determined by liquid chromatography-mass
spectrometry (LC-MS) according to validated clinical methods.
Luminex cytokine analysis
Murine lungs were harvested and immediately homogenised in 1 ml
phosphate-buffered saline (PBS) per 100  mg tissue. Lung
homogenates were centrifuged at 3000 g for 10  minutes and
supernatants snap-frozen in liquid nitrogen. Cytokine
quantification was performed with a Luminex 200 analyser by
Fluorokine® multianalyte profiling (MAP) and according to the
manufacturer’s instructions (Luminex, USA).
Estimation of fungal burden
For in vivo studies, whole lungs were homogenised in 1 ml PBS
per 100 mg lung tissue and DNA extracted with the DNeasy Blood
and Tissue Kit (Qiagen) according to the manufacturer’s
instructions. Fungal burden was estimated by semi-quantitative
real-time PCR as described, after normalisation to murine β-actin
(White et al., 2006). For in vitro studies, fungal burden was analysed
by measuring A. fumigatus 18S rRNA (GenBank accession number
AB008401) levels by real time PCR as previously described (Werner
et al., 2009). The murine BALB/c-derived MH-S alveolar
macrophage cell line was pre-treated either with 10 ng/ml FK506
for 1 hour or with vehicle, and infected with resting conidia (A.
fumigatus CEA10; multiplicity of infection, MOI, 1:1) for 6 hours.
Results were calculated as fold change against non-FK506 treated
cells by the ΔCt method, whereby the input was adjusted to murine
HPRT levels (forward 5-GTAATGATCAGTCAACGGGGGAC-
3; reverse 5-GCAAGCTTGCAACCTTAACCA-3).
Flow cytometry
Mice were sacrificed and bronchoalveolar lavage performed by
tracheal cut-down followed by intubation with a 20 Venflon
intravenous catheter (Becton Dickinson). Bronchoalveolar lavage
was performed by instillation of 1 ml of PBS twice. Cell suspensions
were labelled with the following antibodies: anti-CD16/32
(blocking; eBioscience), anti-Ly-6G-BV421 (BioLegend), anti-
F4/80-APC/Cy7 (BioLegend), anti-CD11c-FITC (eBioscience) and
anti-CD45-PE/Cy7 (eBioscience). Cells were fixed with 4%
paraformaldehyde and acquired on a Fortessa flow cytometer.
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